肺动脉高压治疗的个体参与者数据网状Meta分析
本研究基于美国FDA提交的20项PAH三期随机试验、6811例患者的个体数据开展网状Meta分析,按内皮素、一氧化氮、前列环素三条通路分组比较疗效。结果显示各通路药物均显著改善12或16周6分钟步行距离并减少临床恶化事件,且疗效在年龄、体质指数、高血压、糖尿病和冠心病上存在异质性。
要点
- 三条通路药物均较安慰剂显著提高6分钟步行距离并减少临床恶化
- 内皮素+一氧化氮联合通路效应量最大,前列环素吸入/口服最小
- 年龄、BMI、高血压、糖尿病、冠心病患者疗效存在显著异质性
核心结论
- 靶向三条传统通路的药物均显著改善PAH结局,但部分合并症患者存在显著疗效异质性,需个体化研究。
研究设计与样本
- 基于美国FDA提交的20项PAH三期随机临床试验、共6811例患者的个体参与者数据网状Meta分析,药物按内皮素、一氧化氮、前列环素通路分组。
主要发现
- 校正协变量后,内皮素+一氧化氮通路β为43.7 m(95%CI 32.9,54.4),一氧化氮通路29.4 m(22.6,36.3),内皮素通路25.3 m(19.8,30.8),前列环素口服/吸入19.1 m(14.2,24.0)、静脉/皮下24.4 m(15.1,33.7),均较安慰剂显著提高12或16周6分钟步行距离。
- 治疗亦显著降低临床恶化事件可能性。
- 年龄、体质指数、高血压、糖尿病和冠心病存在显著治疗效应异质性。
临床怎么用
- 对PAH患者可依据三条通路选择已证实改善运动能力和临床恶化的药物。
- 合并高血压、糖尿病、冠心病等患者应注意疗效异质性,避免一刀切用药。
局限性
- 仅纳入提交FDA的三期随机试验个体数据,研究结论受原始试验人群与设计限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Effective therapies that target three main signalling pathways are approved to treat pulmonary arterial hypertension (PAH). However, there are few large patient-level studies that compare the effectiveness of these pathways. The aim of this analysis was to compare the effectiveness of the treatment pathways in PAH and to assess treatment heterogeneity. METHODS: A network meta-analysis was performed using individual participant data of 6811 PAH patients from 20 Phase III randomized clinical trials of therapy for PAH that were submitted to the US Food and Drug Administration. Individual drugs were grouped by the following treatment pathways: endothelin, nitric oxide, and prostacyclin pathways. RESULTS: The mean (±standard deviation) age of the sample was 49.2 (±15.4) years; 78.4% were female, 59.7% had idiopathic PAH, and 36.5% were on background PAH therapy. After covariate adjustment, targeting the endothelin + nitric oxide pathway {β: 43.7 m [95% confidence interval (CI): 32.9, 54.4]}, nitric oxide pathway [β: 29.4 m (95% CI: 22.6, 36.3)], endothelin pathway [β: 25.3 m (95% CI: 19.8, 30.8)], and prostacyclin pathway [oral/inhaled β: 19.1 m (95% CI: 14.2, 24.0), intravenous/subcutaneous β: 24.4 m (95% CI: 15.1, 33.7)] significantly increased 6 min walk distance at 12 or 16 weeks compared with placebo. Treatments also significantly reduced the likelihood of having clinical worsening events. There was significant heterogeneity of treatment effects by age, body mass index, hypertension, diabetes, and coronary artery disease. CONCLUSIONS: Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH, with significant treatment heterogeneity in patients with some comorbidities. Randomized clinical trials are warranted to identify the most effective treatment strategies in a personalized approach.
引用
- Moutchia J, McClelland RL, Al-Naamani N, et al. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis. Eur Heart J. 2024. PMID: 38416633. doi:10.1093/eurheartj/ehae049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。